Overcoming Access Barriers and Step-Edit Challenges in IgA Nephropathy

The nephrologists examined real-world use of emerging therapies for IgA nephropathy (IgAN), which is frequently limited by payer policies, prior authorization requirements, and high out-of-pocket costs that delay treatment initiation. These administrative hurdles can be particularly problematic in a disease where early intervention is critical to slowing irreversible kidney damage. Step-edit requirements that mandate a trial of systemic corticosteroids before newer targeted therapies create additional barriers and may not align with contemporary clinical guidelines. For many patients with IgAN, prolonged steroid exposure is inappropriate due to modest efficacy, significant toxicity risks, and the availability of therapies with more favorable safety profiles. Steroid mandates can also delay access for patients with contraindications such as diabetes, obesity, infection risk, or psychiatric comorbidities. From a health-system perspective, these policies increase provider burden, prolong time to treatment, and may worsen long-term renal outcomes. Addressing these barriers will require stronger real-world evidence, clearer guideline integration, and pharmacist-led advocacy to support policy changes that reflect current standards of care.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, Advocacy Strategies and the Expanding Role of Novel Therapies in IgA Nephropathy, features the panelists advancing their conversation on IgA nephropathy and focusing on additional clinical considerations.